Enter the era of Varian Proton Therapy

USA Headquarters

Palo Alto, CA

Telephone: 650.424.5700

Toll Free: 800.544.4636

Latin American Headquarters

Miami, FL USA

Telephone: 305.929.1970

RAD 9999A Copyright © 2008 Varian Medical Systems, Inc. Printed in USA. 08/08

Varian and Varian Medical Systems are registered trademarks of Varian Medical Systems, Inc. The names of other companies and products herein

are used for identification purposes only and may be trademarks or registed trademarks of their respective owners.

European Headquarters

International AG

Zug, Switzerland

Telephone: 41.41.749.884

Bergisch Gladbach, Germany

Telephone: 49.22.04.842500

Fax: 49.22.04.842501

Asian Headquarters

Pacific, Inc.

Kowloon, Hong Kong

Telephone: 85.22.724.2836

Australian Headquarters

Australasia Pty Ltd.

Sydney, Australia

Telephone: 61.2.9485.0100

www. varian.com

VARIAN MEDICAL SYSTEMS PARTICLE THERAPY

Disclaimer

The proton therapy device technology described in this

brochure has not been cleared by the US Food and Drug

Administration (“FDA”) for clinical use and is in development.

The FDA has a unique set of standards for proton therapy

devices because the entire proton therapy facility must be

built for the specific device. For these types of devices, the

FDA allows proton therapy sponsors to discuss projects with

potential customers and to engage in contracts /orders to

build proton therapy facilities and /or to purchase proton

therapy equipment. However, contracts or other engagements

specific to clinical practice are strictly prohibited; that is, no

engagements or agreements for patient scheduling or

physician group practice to use proton therapy equipment are

permitted in advance of FDA clearance.

For over 50 years Varian has led the way in cancer

treatment, introducing innovative solutions and launching

technologies that have revolutionized treatment. While we

take great pride in our success, we attribute much of it to

our close collaboration with clinical experts. Their involvement,

coupled with our dedication to excellence, has produced

a history of results that is simply unmatched in the

industry. • Now, Varian expands its cancer treatment

offering with the first and only fully Varian compatible

Proton Therapy system from a single vendor. System

compatibility means true integration, resulting in more

time for your clinical staff to focus on patients and

innovative care. • For more than a decade, Varian has been

making significant advances in the proton therapy field,

being the first to bring proton therapy treatment

planning to the U.S. market. When you partner with

Varian, you choose the undisputed leader in oncology

solutions enabling you to maintain your status as a member

of the select medical community that is leading the way

in cancer care.

Varian’s Proton Therapy Development Program a milestone in cancer treatment

F U T U R E C H O R E O G R A P H E R

When your facility is among the world’s top cancer

treatment centers, your next decision-making step is

relatively easy. In order to continue to be the best at

what you do, you need to have the most advanced tools.

You seek “state-of-the-art” technology. The question is,

should you embrace emerging technologies or maintain

the status quo? The answer will undoubtedly define the

future of your facility. • The investment typically required

for a proton therapy center, along with the patient

demographics necessary to warrant such an expense,

usually prevents the establishment of many centers

within a given location. A determining fact is that

leadership roles in proton therapy cancer treatment, once

taken, will leave little or no room for others to follow.

Once a community is served, once a treatment center

establishes its reputation as a leader, other facilities tend

to recede into secondary roles. • Making the right choice

today for the future of your organization is paramount.

It’s what’s nextfor the world’s top cancer treatment centers

F U T U R E G R A N D P A R E N T

All cancer facilities, like all patients, are unique. But all

cancer facilities share the common goal of wanting to

better serve their community. Today, less than one percent

of all radiotherapy patients who could benefit significantly

from having protons for all or part of their treatment get

treated with proton therapy.* Our commitment to helping

you improve this percentage makes Varian an ideal proton

therapy partner. • Our proton therapy solution is being

developed with efficiency, cost savings and accuracy in

mind to give you a streamlined proton therapy process for

prescription, planning, scheduling, delivery, and quality

assurance. We have designed our system to be adaptive

with maximum scalability meaning that a hospital can start

small and expand as its practice grows. It is designed to

accommodate future technologies, as well as address the

needs of your facility. Larger treatment centers will find

that the Varian system is capable of servicing the most

challenging population demands as well. • In addition, this

advanced mode of therapy may present a tremendous

opportunity for your center to attract new patients and

draw additional superior talent to your facility.

An uncommon approach to common goals

* http://new.reil lycomm.com/imaging/article_detail.php?id=311

F U T U R E E N V I R O N M E N T A L R E S E A R C H E R

As a world leader in the manufacturing of medical

devices and software for treating cancer, Varian is a

company with extensive global resources. Employing

over 4,000 people, with sales exceeding 1.5 billion, Varian

is in the position of being able to develop, refine, and

service its product offerings in ways that many other

companies simply cannot. • The Proton Therapy system

from Varian stands as a perfect example of how the depth

and breadth of Varian’s resources can help solve problems,

simplify operational issues, and move cancer treatment

forward. Varian’s comprehensive Proton Therapy offering

is unique in the industry, enabling you and your staff to

link advanced proton therapy to most existing radiation

therapy services, helping to maximize efficiencies, reduce

learning curves and assure that the system availability will

be maintained at a high level. • It comes down to one of

the simplest facts of healthcare: that better outcomes can

produce a more perfect world. And that’s the world we

would like to see in the not-so-distant future.

Someday, in a more perfect world, we hope everyone will have access to Varian Proton Therapy

F U T U R E N O B E L L A U R E A T E

Varian has combined its comprehensive treatment delivery, planning,

and information management system into a unique, state-of-the-art

Intensity Modulation Proton Therapy (IMPT) solution in which every

component is engineered to work together. • IMPT treatments are

critical because they enable clinicians to tailor and maximize the radi-

ation dose to a tumor, while delivering lower global dose to healthy

tissue. Optimal IMPT delivery is achieved through accurate beam

scanning. Varian’s technology permits true IMPT delivery by painting

the dose to the tumor essentially reducing neutron dose to the

patient. When you combine Varian’s superb scanning technology with

the high performance of Varian’s new 250 MeV Superconducting

Cyclotron, you obtain smooth IMPT proton delivery. • Varian’s new

250 MeV Superconducting Cyclotron is a key component of the

Varian Proton Therapy system. Its state-of-the-art design stands as a

milestone in cancer treatment allowing facilities to deliver precise

proton therapy. Its compact size requires minimal space and its

superconducting design results in high extraction efficiency, reliability,

and efficient maintenance. • In today’s market, Varian’s 250 MeV

Superconducting Cyclotron is a genuine advancement in proton

cancer therapy. Only Varian can provide you with such a sophisticated

solution backed by world-renowned customer support and more than

a half century of experience in radiation oncology.

The technology behind optimal integration, IMPT, and the Cyclotron

V A R I A N S U P E R C O N D U C T I N G C Y C L O T R O N

The proton therapy device technology described in this

brochure has not been cleared by the US Food and

Drug Administration (“FDA”) for clinical use and is in

development. The FDA has a unique set of standards for

proton therapy devices because the entire proton therapy

facility must be built for the specific device. For these types

of devices, the FDA allows proton therapy sponsors to

discuss projects with potential customers and to engage in

contracts /orders to build proton therapy facilities and /or

to purchase proton therapy equipment. However,

contracts or other engagements specific to clinical

practice are strictly prohibited; that is, no engagements

or agreements for patient scheduling or physician group

practice to use proton therapy equipment are permitted

in advance of FDA clearance.

Disclaimer

Enter the era of Varian Proton Therapy

USA Headquarters

Palo Alto, CA

Telephone: 650.424.5700

Toll Free: 800.544.4636

Latin American Headquarters

Miami, FL USA

Telephone: 305.929.1970

RAD 9999A Copyright © 2008 Varian Medical Systems, Inc. Printed in USA. 08/08

Varian and Varian Medical Systems are registered trademarks of Varian Medical Systems, Inc. The names of other companies and products herein

are used for identification purposes only and may be trademarks or registed trademarks of their respective owners.

European Headquarters

International AG

Zug, Switzerland

Telephone: 41.41.749.884

Bergisch Gladbach, Germany

Telephone: 49.22.04.842500

Fax: 49.22.04.842501

Asian Headquarters

Pacific, Inc.

Kowloon, Hong Kong

Telephone: 85.22.724.2836

Australian Headquarters

Australasia Pty Ltd.

Sydney, Australia

Telephone: 61.2.9485.0100

www. varian.com

VARIAN MEDICAL SYSTEMS PARTICLE THERAPY

Disclaimer

The proton therapy device technology described in this

brochure has not been cleared by the US Food and Drug

Administration (“FDA”) for clinical use and is in development.

The FDA has a unique set of standards for proton therapy

devices because the entire proton therapy facility must be

built for the specific device. For these types of devices, the

FDA allows proton therapy sponsors to discuss projects with

potential customers and to engage in contracts /orders to

build proton therapy facilities and /or to purchase proton

therapy equipment. However, contracts or other engagements

specific to clinical practice are strictly prohibited; that is, no

engagements or agreements for patient scheduling or

physician group practice to use proton therapy equipment are

permitted in advance of FDA clearance.